# OnCo record trastuzumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/trastuzumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "trastuzumab" ;
  schema:name "Trastuzumab"@en ;
  schema:alternateName "Trastuzumab and Hyaluronidase-oysk"@en, "Herceptin Hylecta"@en, "Herceptin (and biosimilars, Phesgo with pertuzumab)" ;
  schema:description "The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable."@en ;
  schema:url <https://onco.cc/drugs/trastuzumab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Trastuzumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q412616> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-HER2)" ;
  onco:approval "US 1998: HER2+ metastatic breast cancer", "US 2006: Adjuvant HER2+ breast cancer", "US 2010: HER2+ gastric cancer" ;
  onco:related <https://onco.cc/pairings/tucatinib-triplet-brain-mets/>, <https://onco.cc/biomarkers/her2-ihc-3-plus/>, <https://onco.cc/biomarkers/her2-ish-amplified/> ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/gastric-her2-positive/>, <https://onco.cc/cancers/salivary-duct-carcinoma/>, <https://onco.cc/cancers/her2-positive-early-breast-cancer/>, <https://onco.cc/cancers/endometrial-p53-abnormal/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/nippon-kayaku/>, <https://onco.cc/companies/halozyme/> ;
  onco:trials <https://onco.cc/trials/nct07518173/>, <https://onco.cc/trials/nct06435429/>, <https://onco.cc/trials/nct07196774/>, <https://onco.cc/trials/nct06891833/>, <https://onco.cc/trials/nct04430738/>, <https://onco.cc/trials/nct05081609/>, <https://onco.cc/trials/nct06324357/>, <https://onco.cc/trials/nct07102381/>, <https://onco.cc/trials/nct06589830/>, <https://onco.cc/trials/nct05458674/>, <https://onco.cc/trials/nct05980481/>, <https://onco.cc/trials/nct06731478/>, <https://onco.cc/trials/nct03379428/>, <https://onco.cc/trials/nct07497386/>, <https://onco.cc/trials/nct05785741/>, <https://onco.cc/trials/nct06057610/>, <https://onco.cc/trials/nct06764875/>, <https://onco.cc/trials/nct04208178/>, <https://onco.cc/trials/nct06771622/>, <https://onco.cc/trials/nct04873362/>, <https://onco.cc/trials/nct07047365/>, <https://onco.cc/trials/nct00781612/>, <https://onco.cc/trials/nct07007559/>, <https://onco.cc/trials/nct06686394/>, <https://onco.cc/trials/nct02320435/>, <https://onco.cc/trials/nct05417594/>, <https://onco.cc/trials/nct07315750/>, <https://onco.cc/trials/nct04379596/>, <https://onco.cc/trials/nct07069712/>, <https://onco.cc/trials/nct07679360/>, <https://onco.cc/trials/nct04721977/>, <https://onco.cc/trials/nct04579380/>, <https://onco.cc/trials/mountaineer/>, <https://onco.cc/trials/nct07140393/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/>, <https://onco.cc/key-papers/paper-toga-trastuzumab-gastric-lancet-2010/>, <https://onco.cc/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/>, <https://onco.cc/key-papers/paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011/>, <https://onco.cc/key-papers/paper-javle-mypathway-her2-biliary-lancet-oncol-2021/> .